Clinical Chemistry · 1996 · 70 citations · 15 references
MedicinePathologyDiagnostic PathologyEarly DetectionGastroenterologyBiomarkers In PathologyDiagnostic Test EvaluationPancreatic DiseasesPancreatic DisordersPancreatic PathologyAccuracyBiomarkers Of SeverityClinical Enzyme MarkersClinical Utility AnalysisClinical Utility AssessmentDiagnostic Testing AccuracyDisease Severity EstimationPancreatic Enzyme Testing
We examined the clinical utility of urine trypsinogen-2 as a marker of acute pancreatitis (AP). Fifty-nine patients with AP, 42 with acute abdominal diseases of extrapancreatic origin, and 63 without evidence of acute abdominal disease were studied. Urine trypsinogen-2 was determined by a time-resolved immunofluorometric assay. As reference methods we used serum trypsinogen-2, urine amylase, and serum amylase. The diagnostic accuracy of the markers was evaluated by receiver-operating characteristic (ROC) analysis. At admission, urine trypsinogen-2 differentiated patients with AP from controls with high accuracy. The area under the ROC curve (AUC) was 0.978, which was equal to that of serum trypsinogen-2 (0.998) and serum amylase (0.969) and significantly larger than that of urine amylase. For differentiation between severe and mild AP, urine trypsinogen-2 (0.730) was equal to serum trypsinogen-2 (0.721), and clearly better than amylase in serum and urine. These results suggest that determination of urine trypsinogen-2 is a useful test to detect AP and to evaluate disease severity.
15
Acute pancreatitis: a lethal disease of increasing incidence.
Anthony P. Corfield, M J Cooper, R C N Williamson · Gut · 1985 · 324 citations · Full text